<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33449454</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>448</StartPage><EndPage>455</EndPage><MedlinePgn>448-455</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51299</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To explore the associations between serum creatinine and creatine kinase (CK) levels with survival in male and female ALS patients.</AbstractText><AbstractText Label="METHODS">A prospective cohort study was carried out including 346 ALS patients with repeated serum creatinine and CK measurements. Kaplan Meier analysis and multivariable Cox regression were used to perform survival analysis.</AbstractText><AbstractText Label="RESULTS">There were 218 male and 128 female patients, and the males had significantly higher baseline serum creatinine and CK levels than females. After multivariable Cox regression analysis, lower baseline serum creatinine levels were associated with a short survival in both male (&#x2264;61&#xa0;&#x3bc;mol/L, HR: 1.629; 95%CI: 1.168-2.273) and female ALS patients (&#x2264;52&#xa0;&#x3bc;mol/L, HR: 1.677; 95%CI: 1.042-2.699), whereas, the serum CK levels were not correlated with survival. Besides, creatinine levels were positively associated with ALSFRS-R scores, and inversely with the decline rate of ALSFRS-R per month. During follow-up, serum creatinine levels tended to be decreased along with the disease progression, and the higher decline rate of creatinine per month (&gt;1.5) showed significantly shorter survival, compared to the lower group (&#x2264;1.5) (30.0&#xa0;months vs. 65.0&#xa0;months, Chi square&#xa0;=&#xa0;28.25, P&#xa0;&lt;&#xa0;0.0001).</AbstractText><AbstractText Label="INTERPRETATION">Serum creatinine could be a reliable and easily accessible prognostic chemical marker for ALS, and decreased baseline creatinine levels could predict a poor prognosis and a short survival in both male and female ALS patients.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Qi-Fu</ForeName><Initials>QF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Liu-Qing</ForeName><Initials>LQ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qi-Jie</ForeName><Initials>QJ</Initials><Identifier Source="ORCID">0000-0002-1311-5582</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>15</Day><Hour>12</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33449454</ArticleId><ArticleId IdType="pmc">PMC7886033</ArticleId><ArticleId IdType="doi">10.1002/acn3.51299</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet 2017;390:2084&#x2013;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Chalabi A, Hardiman O, Kiernan MC, et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol 2016;15:1182&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber N, Shaw PJ. Biomarkers in amyotrophic lateral sclerosis: a review of new developments. Curr Opin Neurol 2020;33:662&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">32796280</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Bovio G, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population&#x2010;based study. JAMA Neurol 2014;71:1134&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson SB, Kasarskis EJ, Hu N, et al. Relationship of creatine kinase to body composition, disease state, and longevity in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:473&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5595062</ArticleId><ArticleId IdType="pubmed">26312548</ArticleId></ArticleIdList></Reference><Reference><Citation>Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">10086395</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF. Neuroprotective effects of creatine. Amino Acids 2011;40:1305&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pubmed">21448659</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Guo X, Huang R, et al. An exploratory study of serum creatinine levels in patients with amyotrophic lateral sclerosis. Neurol Sci 2014;35:1591&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pubmed">24782098</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Eijkemans MJC, Ferguson TA, et al. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry 2018;89:156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800333</ArticleId><ArticleId IdType="pubmed">29084868</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, et al. The PRO&#x2010;ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D, Bejan&#x2010;Angoulvant T, Patin F, et al. Plasma creatinine and amyotrophic lateral sclerosis prognosis: a systematic review and meta&#x2010;analysis. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:199&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">30961401</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas&#x2010;Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 2012;135:847&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H, Cui L, Liu M, et al. Creatine kinase level and its relationship with quantitative electromyographic characteristics in amyotrophic lateral sclerosis. Clin Neurophysiol 2018;129:926&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">29550653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Garofalo DC, Santella RM, et al. Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2020;21:263&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7373369</ArticleId><ArticleId IdType="pubmed">32276554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, Hashizume A, Hijikata Y, et al. Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. J Neurol 2019;266:2952&#x2013;2961.</Citation><ArticleIdList><ArticleId IdType="pubmed">31456060</ArticleId></ArticleIdList></Reference><Reference><Citation>Prior DE, Stommel E, Lawson VH, et al. Distribution of serum creatine kinase levels in amyotrophic lateral sclerosis. Muscle Nerve 2020;61:E16&#x2013;E18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7024640</ArticleId><ArticleId IdType="pubmed">31811651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq MK, Lee E, Bradburn M, et al. Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis. Eur J Neurol 2016;23:1071&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">27029589</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinaki M, Mulder DW. Amyotrophic lateral sclerosis: relationship between serum creatine kinase level and patient survival. Arch Phys Med Rehabil 1986;67:169&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">3954579</ArticleId></ArticleIdList></Reference><Reference><Citation>Felice KJ, North WA. Creatine kinase values in amyotrophic lateral sclerosis. J Neurol Sci 1998;160(Suppl 1):S30&#x2013;S32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9851645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>